UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
In connection with the strategic restructuring and pipeline prioritization of Sarepta Therapeutics, Inc. (the “Company”), Bilal Arif’s employment will end effective September 16, 2025. Mr. Arif served as the Executive Vice President, Chief Technical Operations Officer of the Company until August 12, 2025 and will serve as Special Advisor to the President for the remainder of his employment. The Company thanks Mr. Arif for his substantial contributions during a transformational period for the Company and wishes him well.
The Company entered into a Separation and Consulting Agreement and General Release (the “Agreement”) with Mr. Arif dated August 12, 2025, pursuant to which he will remain a consultant to the Company following his termination of employment through December 31, 2025. Pursuant to the terms of the applicable equity award agreements, the outstanding equity awards issued to Mr. Arif as of August 12, 2025 will continue to vest through the period in which Mr. Arif continues to be employed by or provide consulting services to the Company. Under the Agreement, the Company has agreed to pay Mr. Arif severance in the lump sum amount of $576,700 as well as a consulting fee of $400 per hour for the consulting services provided.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Sarepta Therapeutics, Inc. | ||||||
| Date: August 13, 2025 | By: | /s/ Douglas S. Ingram | ||||
| Douglas S. Ingram Chief Executive Officer | ||||||